荆花胃康胶丸联用富马酸伏诺拉生抗幽门螺杆菌治疗的临床疗效评估  

Evaluation of the clinical efficacy of Jinghua Weikang capsule combined with vonorason fumarate in Helicobacter pylori eradication treatment

作　　者：滕晓丽[1] 周晓黎[1] 张书[1] 廖艳[1] 万莹[1] 杨健[1] 胡伟[1] TENG Xiao-li;ZHOU Xiao-li;ZHANG Shu;LIAO Yan;WAN Ying;TANG Jian;HU Wei(Department of Gastroenterology,Wuhan First Hospital,430022,Wuhan,Hubei,China)

机构地区：[1]武汉市第一医院消化内科,湖北武汉430022

出　　处：《临床消化病杂志》2025年第1期1-5,共5页Chinese Journal of Clinical Gastroenterology

基　　金：武汉市卫健委中医药项目(No:WZ22C37);伦理批件号:武卫一院伦审[2022]35号。

摘　　要：[目的]探究荆花胃康胶丸联用富马酸伏诺拉生抗幽门螺杆菌(Hp)治疗的临床疗效评估。[方法]选取收治的126例Hp阳性脾胃湿热证慢性胃炎患者,按就诊顺序抽签随机分为研究组与对照组,每组63例。研究组采用荆花胃康胶丸+富马酸伏诺拉生+大剂量阿莫西林三联组治疗,对照组采用标准四联疗法(胶体果胶铋胶囊+克拉霉素缓释片+阿莫西林胶囊+艾司奥美拉唑)治疗,比较2组患者Hp根除率、复发率、药品性价比评估、生活质量、中医证候积分、临床疗效和不良事件。[结果]与对照组相比,研究组的复发率较低,差异有统计学意义(P<0.05);同样连续服用2周药物,研究组价格较低。治疗后,对照组和研究组患者SF-36评分较治疗前显著升高,研究组高于对照组(P<0.05)。治疗后,对照组和研究组患者中医证候积分较治疗前显著降低,研究组低于对照组(P<0.05)。研究组总有效率(91.67%,55/60)高于对照组(70.00%,42/60),2组比较P<0.05。研究组不良反应发生率低于对照组(P<0.05)。[结论]荆花胃康胶丸联用富马酸伏诺拉生抗Hp治疗的效果显著,可降低Hp复发率,提高患者生活质量,有效改善患者中医证候,并且安全可靠。[Objective]To explore the clinical efficacy of Jinghua Weikang capsule combined with vorolaxen fumarate in the treatment of Helicobacter pylori(Hp).[Methods]The study enrolled 126patients with Hpinfected chronic gastritis of damp-heat syndrome of spleen and stomach from January 2021to January 2022,and they were randomly grouped into two groups according to the order of treatment.The study group(n=63)was treated with Jinghua Weikang capsule+vorolaxen fumarate+high-dose amoxicillin,the control group(n=63)was treated with standard quadruple therapy(colloidal bismuth pectin capsule+clarithromycin sustained-release tablets+amoxicillin capsule+esomeprazole).The Hperadication rate,recurrence rate,drug cost-effectiveness evaluation,quality of life,TCM syndrome score,clinical efficacy and adverse events were compared between the two groups.[Results]Compared with the control group,the eradication rate of recurrence rate was lower(P<0.05).After taking the drug for 2weeks,the study group spent less than the control group.After treatment,the SF-36score of patients in the both group was obviously higher than that before treatment,and the study group was higher than the control group(P<0.05).After treatment,the TCM syndrome score of patients in the control group and the research group was obviously lower than that before treatment,and the research group was lower than the control group(P<0.05).The total effective rate of the study group(91.67%,55/60)was higher than that of the control group(70.00%,42/60)(P<0.05).The incidence of adverse reactions in the study group was lower than that in the control group(P<0.05).[Conclusion]The combination of Jinghua Weikang Jiaowan and Fumarate Vonorasone has a significant therapeutic effect on Hp,which can reduce the recurrence rate of Hp,improve the quality of life of patients,effectively improve traditional Chinese medicine syndromes,and is safe and reliable.

关 键 词：慢性胃炎 荆花胃康胶丸 富马酸伏诺拉生 幽门螺杆菌 

分 类 号：R573.3[医药卫生—消化系统]